GlassScriptPhysician profile
Erik O Gilbertson
NPI 1326158767
$22,344.19
in general payments reported to CMS, 2019-2025
26 companies · $792 in 2025
The $792 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $122 · 2021: $60.73 · 2022: $1,021 · 2023: $1,096 · 2024: $747 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008 · Education: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.35 |
| Education | $626.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16,389.74 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $1,455.00 | 2019 | |
| Janssen Biotech, INC. | $1,397.37 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $560.77 | 2023-2025 | Ilumya |
| Janssen Scientific Affairs, LLC | $500.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $278.77 | 2022-2023 | Sotyktu |
| Abbvie INC. | $221.18 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $206.92 | 2019-2022 | |
| Pfizer INC. | $171.47 | 2019-2023 | |
| Incyte Corporation | $157.66 | 2022-2025 | Opzelura |
| Ucb, INC. | $148.85 | 2025 | Bimzelx |
| Leo Pharma INC. | $122.36 | 2019-2025 | Adbry |
| Blueprint Medicines Corporation | $121.83 | 2022 | |
| Lilly USA, LLC | $112.49 | 2019-2024 | Taltz |
| Regeneron Pharmaceuticals, INC. | $108.96 | 2023 | Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $87.97 | 2020-2024 | Dupixent |
| Smith+Nephew, INC. | $63.10 | 2024 | Stravix |
| Amgen INC. | $41.45 | 2019-2024 | Otezla |
| Almirall LLC | $36.98 | 2022 | |
| Genentech USA, INC. | $32.58 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.86 | 2024 | Spevigo |
| Celgene Corporation | $24.10 | 2019 | |
| Genzyme Corporation | $23.41 | 2019 | |
| Vyne Pharmaceuticals INC. | $23.30 | 2021 | |
| Galderma Laboratories, L.P. | $18.07 | 2025 | Nemluvio |
| Glenmark Therapeutics INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Gilbertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.